|  |  |
| --- | --- |
| Patients with hematologic cancer | #1 Lymphoma [Mesh] OR Myeloma[Mesh] OR Leukemia[Mesh] OR Lymphoma [tiab] OR Myeloma[tiab] OR Leukemia[tiab] OR Hematologic [Mesh] OR Hematologic[tiab] |
| PFS/ORR | #2 progression free survival[Mesh] OR disease progression[Mesh] OR progression free survival[tiab] OR PFS[tiab] OR objective response[tiab] OR ORR[tiab] OR investigator OR independent review |
| Cochrane filter for RCTs | #3 randomized controlled trial [pt]  #4 controlled clinical trial [pt]  #5 randomized [tiab]  #6 placebo [tiab]  #7 drug therapy [sh]  #8 randomly [tiab]  #9 trial [tiab]  #10 groups [tiab]  #11 randomized controlled trial [pt]  OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab]  OR trial [tiab]OR groups [tiab]  #12 animals [mh] NOT humans [mh]  #13 randomized controlled trial [pt]  OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab]  OR trial [tiab]OR groups [tiab]  NOT animals [mh] NOT humans [mh] |
| Equation | #1 AND #2 AND #13 |

Blinded Central Independent review (BCIR)

Centralized Independent review

Example paper:

1. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma